Trials / Completed
CompletedNCT00093171
Study Evaluating rFIX; BeneFIX® in Hemophilia B
An Open-label Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) With Hemophilia B (FIX:C ≤2%)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rFIX |
Timeline
- Primary completion
- 2005-05-01
- Completion
- 2005-05-01
- First posted
- 2004-10-07
- Last updated
- 2009-08-21
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00093171. Inclusion in this directory is not an endorsement.